A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
A.History and Development of the Company Our legal and commercial name is Abivax SA. We were incorporated as a société anonyme (limited liability company) under the laws of France on December 4, 2013 for a period of 99 years until December 22, 2112, subject to extension or early dissolution and registered at the Paris Trade and Company Register on December 27, 2013 under the number 799 363 718. Our principal executive offices are located at 7-11 boulevard Haussmann 75009 Paris, France, and our telephone number is +33 (0) 1 53 83 09 63. We have one wholly owned subsidiary, Abivax LLC, a Delaware limited liability company, formed on March 20, 2023. Our agent for service of process in the United States is CT Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C. 20005. We have been listed on Euronext Paris since June 2015.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - |
| Net Income | -190M | -190M | -160M | -64M | -50M |
| EPS | $-2.41 | $-2.41 | $-2.96 | $-2.67 | $-2.58 |
| Free Cash Flow | -167M | -167M | -106M | -57M | -53M |
| ROIC | 4.8% | 10.5% | -75.4% | 27.7% | 86.5% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 4.06 | 0.67 | 9.51 | 3.21 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | 13M | 13M | -130M | 4.8M | 14M |
| Operating Margin | 0.0% | - | - | - | - |
| ROE | -434.3% | -149.0% | -145.4% | -366.8% | -306.9% |
| Shares Outstanding | 79M | 79M | 54M | 80M | 79M |
| Metric | 2021 | 2022 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | 56M | 51M | 112M | 158M | 158M |
| SG&A | 6.6M | 7.9M | 24M | 36M | 36M |
| EBIT | 14M | 4.8M | -130M | 13M | 13M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -50M | -64M | -160M | -190M | -190M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | 86.5% | 27.7% | -75.4% | 10.5% | 4.8% |
| ROE | -306.9% | -366.8% | -145.4% | -149.0% | -434.3% |
| ROA | -77.4% | -160.2% | -73.4% | -66.2% | -85.9% |
| Cash Flow | |||||
| Op. Cash Flow | -53M | -57M | -105M | -166M | -166M |
| Free Cash Flow | -53M | -57M | -106M | -167M | -167M |
| Owner Earnings | -54M | -57M | -106M | -168M | -168M |
| CapEx | 55K | 303K | 288K | 691K | 691K |
| Maint. CapEx | 356K | 511K | 768K | 1.2M | 1.2M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 |
| D&A | 356K | 511K | 768K | 1.2M | 1.2M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -156M |
| Cash & Equiv. | 72M | 28M | 274M | 156M | 156M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 3.21 | 9.51 | 0.67 | 4.06 | 0.00 |
| Interest Coverage | 3.4 | 0.7 | -4.3 | 0.7 | 0.7 |
| Equity | 31M | 7.6M | 213M | 44M | 44M |
| Total Assets | 129M | 80M | 355M | 222M | 222M |
| Total Liabilities | 98M | 72M | 142M | 178M | 178M |
| Intangibles | 38M | 19M | 20M | 20M | 20M |
| Retained Earnings | -46M | -87M | -147M | -284M | -284M |
| Working Capital | 51M | -16M | 212M | 83M | 83M |
| Current Assets | 89M | 38M | 310M | 184M | 184M |
| Current Liabilities | 38M | 54M | 98M | 102M | 102M |
| Per Share Data | |||||
| EPS | -2.58 | -2.67 | -2.96 | -2.41 | -2.41 |
| Owner EPS | -0.68 | -0.72 | -1.96 | -2.12 | -2.12 |
| Book Value | 0.39 | 0.10 | 3.93 | 0.55 | 0.55 |
| Cash Flow/Share | -0.67 | -0.71 | -1.95 | -2.11 | -2.39 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 79.1M | 79.6M | 54.1M | 79.1M | 79.1M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -52.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | 728.0 |
| Price/Book | N/A | N/A | 2.7 | 12.8 | 226.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | -18.1% | -29.7% | -1.7% |
| Market Cap | N/A | N/A | 584M | 563M | 9.9B |
| Avg. Price | N/A | N/A | 10.18 | 12.11 | 125.80 |
| Year-End Price | N/A | N/A | 10.80 | 7.12 | 125.80 |
Abivax S.A. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 12.3%.
Abivax S.A. (ABVX) has a 5-year average return on invested capital (ROIC) of 12.3%. This indicates solid capital allocation.
Abivax S.A. (ABVX) has a market capitalization of $9.9B. It is classified as a mid-cap stock.
Abivax S.A. (ABVX) does not currently pay a regular dividend.
Abivax S.A. (ABVX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Abivax S.A. (ABVX) generated $-167 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Abivax S.A. (ABVX) has a debt-to-equity ratio of 4.06. This indicates higher leverage, which may increase financial risk.
Abivax S.A. (ABVX) reported earnings per share (EPS) of $-2.41 in its most recent fiscal year.
Abivax S.A. (ABVX) has a return on equity (ROE) of -149.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for Abivax S.A. (ABVX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Abivax S.A. (ABVX) has a book value per share of $0.55, based on its most recent annual SEC filing.
No recent press releases.